MedPath
HSA Approval

VANCOVER CAPSULES 250MG

SIN16445P

VANCOVER CAPSULES 250MG

VANCOVER CAPSULES 250MG

March 11, 2022

ORIENT EUROPHARMA PTE LTD

ORIENT EUROPHARMA PTE LTD

Regulatory Information

ORIENT EUROPHARMA PTE LTD

ORIENT EUROPHARMA PTE LTD

Therapeutic

Prescription Only

Formulation Information

CAPSULE

**2\. DOSAGE AND ADMINISTRATION** **2.1 Adults** Vancomycin Hydrochloride Capsule is used in treating _C. difficile_-associated diarrhea and staphylococcal enterocolitis. - _C. difficile_-associated diarrhea: The recommended dose is 125 mg administered orally 4 times daily for 10 days. - Staphylococcal enterocolitis: Total daily dosage is 500 mg to 2 g administered orally in 3 or 4 divided doses for 7 to 10 days **2.2 Pediatric Patients (less than 18 years of age)** For both _C. difficile_-associated diarrhea and staphylococcal enterocolitis, the usual daily dosage is 40 mg/kg in 3 or 4 divided doses for 7 to 10 days. The total daily dosage should not exceed 2 g.

ORAL

Medical Information

**1\. INDICATIONS AND USAGE** Vancomycin Hydrochloride Capsule is indicated for the treatment of _C. difficile_-associated diarrhea. Vancomycin Hydrochloride Capsule is also used for the treatment of enterocolitis caused by _Staphylococcus aureus_ (including methicillin-resistant strains) in adult and pediatric patients less than 18 years of age. Limitations of Use - Parenteral administration of vancomycin is not effective for the above infections; therefore, Vancomycin Hydrochloride Capsule must be given orally for these infections. - **Orally administered Vancomycin Hydrochloride Capsule is not effective for other types of infections.** To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Hydrochloride Capsule and other antibacterial drugs, Vancomycin Hydrochloride Capsule should be used only to treat or to prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

**4\. CONTRAINDICATIONS** Vancomycin Hydrochloride Capsule is contraindicated in patients with known hypersensitivity to vancomycin.

A07AA09

vancomycin

Manufacturer Information

ORIENT EUROPHARMA PTE LTD

Orient Pharma Co., Ltd.

Active Ingredients

Vancomycin hydrochloride eqv Vancomycin

250mg

Vancomycin

Documents

Package Inserts

VANCOVER PI.pdf

Approved: March 11, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

VANCOVER CAPSULES 250MG - HSA Approval | MedPath